Nutex Health, Inc.
NUTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.04 | -0.06 | -0.00 |
| FCF Yield | 14.33% | 10.81% | 19.62% | -0.21% |
| EV / EBITDA | 6.35 | 26.17 | 6.98 | 3.85 |
| Quality | ||||
| ROIC | 12.55% | 3.35% | 8.26% | 19.39% |
| Gross Margin | 57.83% | 51.20% | 55.88% | 54.98% |
| Cash Conversion Ratio | 1.61 | 1.28 | 1.15 | 0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 61.79% | 58.92% | 47.01% | 29.83% |
| Free Cash Flow Growth | 33.60% | 45.89% | 14,992.74% | -105.54% |
| Safety | ||||
| Net Debt / EBITDA | 1.20 | 6.35 | 3.47 | 2.50 |
| Interest Coverage | 23.91 | 5.93 | 11.80 | 22.61 |
| Efficiency | ||||
| Inventory Turnover | 35.76 | 52.33 | 29.97 | 40.70 |
| Cash Conversion Cycle | 93.22 | 109.32 | 105.63 | 73.85 |